CLOSTRIDIUM BOTULINUM (BOTULISM)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Minor: Low prevalence, typically non-lethal infection with recovery very likely; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations; No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Clostridium botulinum is a strictly anaerobic, gram-positive, spore-forming rod that produces botulinum neurotoxins (BoNTs), causing botulism—a disease characterized by progressive flaccid paralysis of voluntary muscles. Seven immunologically distinct toxin types (A-G) exist, with a novel type H recently described. Each toxin type has unique geographic distribution and species susceptibility patterns. Swine are generally considered among the LEAST susceptible domestic animals to botulism, and the disease is rare in pigs. The few recorded outbreaks have been associated with consumption of contaminated feed sources including dead fish, decomposing brewery waste, and restaurant waste. Morbidity of 13-29% and mortality of 13-24% have been reported in outbreaks associated with improperly preserved restaurant waste. Clinical signs include weakness, incoordination, staggering, progressive flaccid paralysis, pupil dilation, excessive salivation, and deep labored breathing. Death results from respiratory muscle paralysis. The pig gastrointestinal tract may have low permeability to botulinum toxin, explaining their relative resistance. Diagnosis requires demonstration of toxin in feed, gastrointestinal contents, liver, or serum, typically by mouse bioassay. Prevention requires eliminating opportunities to consume potentially toxic material. Vaccination is not practical due to the disease's rarity.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Botulism is not transmitted from pigs to humans through pork consumption. The chapter states: "Neither disease [tetanus or botulism] is zoonotic; hence, there is no public health concern." Human botulism occurs through consumption of improperly preserved foods containing preformed toxin, typically home-canned goods, not through properly processed pork products.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
Botulism is not transmitted from animals to humans: "Neither disease is zoonotic; hence, there is no public health concern." Both humans and animals acquire botulism through ingestion of preformed toxin; there is no animal-to-human transmission.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
Botulism is feed/environment-associated, not contagious: (1) No direct transmission: Disease results from ingestion of preformed toxin, not animal-to-animal spread; (2) Feed sources: Outbreaks in swine associated with "consumption of dead fish," "decomposing brewery waste," and "restaurant waste"; (3) Environmental spores: Spores are "ubiquitous in soil throughout the United States"; (4) Feed management: "Prevention requires eliminating opportunities to consume potentially toxic material such as spoiled garbage and decomposing animal tissue"; (5) Pig resistance: "the pig apparently is resistant to botulism"—limiting outbreak potential.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Diagnosis is challenging due to disease rarity and test limitations: (1) Clinical suspicion: "A diagnosis of botulism should be considered in afebrile, alert animals with progressive weakness and recumbency"; (2) Exclusion of other causes: "a diagnosis should be made only after thorough investigation and exclusion of other possible diagnoses"; (3) Toxin detection required: "Confirmation of the diagnosis should be based on detection of BoNT in feed, gastrointestinal contents, liver, or serum"; (4) Mouse bioassay: "still the test most frequently used around the world, although the sensitivity of the test is usually low"; (5) Variable sensitivity: "sensitivity of this test is highest for feed, intermediate for gastrointestinal content and liver, and lowest for serum"; (6) No lesions: "There are no specific gross or microscopic lesions."
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Minor: Low prevalence, typically non-lethal infection with recovery very likely
Botulism is rare but can cause significant losses when outbreaks occur: (1) Rare occurrence: "Botulism in swine is rare"; disease is "sporadic"; (2) Outbreak impact: "A morbidity of 13–29% and a mortality of 13–24% were reported in a series of outbreaks of botulism type C in swine associated with consumption of residues from restaurants"; (3) Pig resistance: Swine are "among the least susceptible domestic animals"; (4) Sporadic nature: Outbreaks depend on access to contaminated feed sources.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
No trade implications: (1) Not regulated: Botulism is not a reportable or trade-restricted disease; (2) Rare occurrence: Sporadic cases do not affect market access; (3) No carcass concerns: Affected animals die acutely; toxin does not persist in muscle tissue in ways affecting food safety.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Antimicrobial resistance is not relevant: (1) Toxin-mediated disease: Disease is caused by preformed toxin, not bacterial infection; (2) No antimicrobial treatment role: Antimicrobials do not address toxin already absorbed; (3) Supportive care focus: Treatment aims to prevent further toxin absorption and support respiration.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
Disease management does not involve antimicrobials: (1) Antitoxin treatment: "Antitoxin is the only specific treatment for botulism"; (2) No antimicrobial role: Antimicrobials cannot neutralize toxin or treat the neurological effects; (3) Prevention focus: Management focuses on eliminating access to contaminated feed.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations
Treatment options are limited: (1) Antitoxin: "Antitoxin is the only specific treatment for botulism, and it has been effective in reducing mortality in humans after consumption of toxin-containing food"; (2) Polyvalent required: "Polyvalent antitoxins incorporating the types most commonly present in a geographic area are required for therapy in animals"; (3) Reduce absorption: "Therapy aimed at reducing continued absorption of toxin from the intestine (administration of magnesium sulfate) might be helpful"; (4) Supportive care: Respiratory support may be needed; (5) Limited efficacy: Once toxin is bound, effects are irreversible.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
Vaccination is not practical for swine: (1) Not practical: "Prophylactic immunization with toxoids is not practical in swine because of the infrequent occurrence of the disease"; (2) Toxoid vaccines exist: Botulinum toxoids are used in other species (horses, cattle) but not routinely in swine; (3) Cost-benefit: The rarity of swine botulism does not justify routine vaccination programs.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
Eradication is impossible due to environmental ubiquity: (1) Ubiquitous spores: Spores are "ubiquitous in soil throughout the United States"; (2) Environmental persistence: Spores survive indefinitely in soil and other environments; (3) Multiple wildlife sources: Associated with "contaminated forage," "decomposing animal carcasses," "transport of BoNT by ravens or crows"; (4) Prevention focus: "Prevention requires eliminating opportunities to consume potentially toxic material"—management rather than eradication is the goal.